{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:41:44Z","timestamp":1774543304861,"version":"3.50.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,2,24]],"date-time":"2005-02-24T00:00:00Z","timestamp":1109203200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s00280-004-0967-y","type":"journal-article","created":{"date-parts":[[2005,2,23]],"date-time":"2005-02-23T14:38:23Z","timestamp":1109169503000},"page":"541-551","source":"Crossref","is-referenced-by-count":54,"title":["5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens"],"prefix":"10.1007","volume":"55","author":[{"given":"Omar N.","family":"Al Safarjalani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem H.","family":"Rais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond F.","family":"Schinazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fardos N. M.","family":"Naguib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud H.","family":"el Kouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,2,24]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s002800100292","volume":"48","author":"ON Al Safarjalani","year":"2001","unstructured":"Al Safarjalani ON, Zhou X-J, Naguib FNM, Goudgaon NM, Schinazi RF, el Kouni MH (2001) Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine a uridine phosphorylase inhibitor: implications for chemotherapy. Cancer Chemother Pharmacol 48:145","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s002800100353","volume":"48","author":"ON Al Safarjalani","year":"2001","unstructured":"Al Safarjalani ON, Zhou X-J, Naguib FNM, Shi J, Schinazi RF, el Kouni MH (2001) Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy. Cancer Chemother Pharmacol 48:389","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/0006-2952(96)00102-5","volume":"51","author":"OM Ashour","year":"1996","unstructured":"Ashour OM, Naguib FNM, el Kouni MH (1996) 5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor and 2\u2032,3\u2032,5\u2032-tri-O-acetyluridine, a prodrug of uridine as modulators of plasma uridine concentration: implication for chemotherapy. Biochem Pharmacol 51:1601","journal-title":"Biochem Pharmacol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s002800051002","volume":"45","author":"OM Ashour","year":"2000","unstructured":"Ashour OM, Al Safarjalani ON, Naguib FNM, Goudgaon NM, Schinazi RF, el Kouni MH (2000) Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine an inhibitor of uridine phosphorylase: relevance to chemotherapy. Cancer Chemother Pharmacol 45:351","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0006-2952(00)00342-7","volume":"60","author":"OM Ashour","year":"2000","unstructured":"Ashour OM, Naguib FNM, Panzica RP, Al Safarjalani ON, el Kouni MH (2000) Modulation of 5-fluorouracil host-toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2\u2032,3\u2032,5\u2032-tri-O-acetyluridine, a prodrug of uridine. Biochem Pharmacol 60:427","journal-title":"Biochem Pharmacol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002800000138","volume":"46","author":"OM Ashour","year":"2000","unstructured":"Ashour OM, Naguib FNM, Goudgaon NM, Schinazi RF, el Kouni MH (2000) Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2\u2032,3\u2032,5\u2032-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy. Cancer Chemother Pharmacol 46:235","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/cvr\/17.3.145","volume":"17","author":"J Aussedat","year":"1983","unstructured":"Aussedat J (1983) Effect of uridine supply on glycogen resynthesis after ischaemia in the isolated perfused rat heart. Cardiovasc Res 17:145","journal-title":"Cardiovasc Res"},{"key":"CR8","first-page":"247","volume":"6","author":"J Aussedat","year":"1984","unstructured":"Aussedat J (1984) Uridine incorporation in normal and ischaemic perfused rat heart. Mol Physiol 6:247","journal-title":"Mol Physiol"},{"key":"CR9","first-page":"331","volume":"78","author":"J Aussedat","year":"1982","unstructured":"Aussedat J, Verdetti J, Grably S, Rossi A (1982) Nucleotides uridyliques et glycogene cardiaque: effet de l\u2019administration d\u2019uridine et de ribose chez le rat. J Physiol (Paris) 78:331","journal-title":"J Physiol (Paris)"},{"key":"CR10","first-page":"215","volume":"19","author":"V Bonavita","year":"1964","unstructured":"Bonavita V, Monaco P, Tripi E (1964) Analisi degli effetti centrali di nucleotidi purinici e pirinmidinici e loro derivati III. Esperimenti farmacologici. Acta Neurol (Napoli) 19:215","journal-title":"Esperimenti farmacologici. Acta Neurol (Napoli)"},{"key":"CR11","first-page":"317","volume":"38","author":"B Bonavita","year":"1968","unstructured":"Bonavita B, Zito M (1968) Analisi dell\u2019azione di nucleosidi pirimidinici sull\u2019elettroencefallogramma umano attivato con megimide. Riv Neurol 38:317","journal-title":"Riv Neurol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/01.RES.7.6.847","volume":"7","author":"NM Buckley","year":"1959","unstructured":"Buckley NM, Tsuboi KK, Zeic NJ (1959) Effects of nucleosides on acute left ventricular failure in isolated dog heart. Circ Res 7:847","journal-title":"Circ Res"},{"key":"CR13","first-page":"722","volume":"88","author":"MI Bushma","year":"1980","unstructured":"Bushma MI, Parkhovchenko EI, Peschanskii VS (1980) Effects of cytidine and uridine on the regeneration of the liver in rats poisoned with carbon tetrachloride. Bull Exp Biol Med 88:722","journal-title":"Bull Exp Biol Med"},{"key":"CR14","first-page":"83","volume":"22","author":"TCK Chan","year":"1988","unstructured":"Chan TCK, Markman M, Pfeifle CE, Taetle R, Abramson I, Howell SB (1988) Uridine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 22:83","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF01796261","volume":"44","author":"HM Cherwinski","year":"1995","unstructured":"Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT (1995) Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 44:317","journal-title":"Inflamm Res"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.2042-7158.1986.tb04552.x","volume":"38","author":"JC Cradock","year":"1986","unstructured":"Cradock JC, Vishnuvajjala BR, Chin TF, Hochstein HD, Ackerman SK (1986) Uridine-induced hyperthermia in the rabbit. J Pharm Pharmacol 38:226","journal-title":"J Pharm Pharmacol"},{"key":"CR17","first-page":"565","volume":"356","author":"H-G Dahnke","year":"1975","unstructured":"Dahnke H-G, Mosebach K-O (1975) In-vivo-untersuchungen zur metabolisierung der pyrimidinnucleoside. Hoppe-Seyler\u2019s Z Physiol Chem 356:565","journal-title":"Hoppe-Seyler\u2019s Z Physiol Chem"},{"key":"CR18","first-page":"5364","volume":"45","author":"JW Darnowski","year":"1985","unstructured":"Darnowski JW, Handschumacher RE (1985) Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine. Cancer Res 45:5364","journal-title":"Cancer Res"},{"key":"CR19","first-page":"3490","volume":"46","author":"JW Darnowski","year":"1986","unstructured":"Darnowski JW, Handschumacher RE (1986) Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake. Cancer Res 46:3490","journal-title":"Cancer Res"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1016\/0006-2952(88)90254-7","volume":"37","author":"JW Darnowski","year":"1988","unstructured":"Darnowski JW, Handschumacher RE (1988) Benzylacyclouridine: pharmacokinetics, metabolism and biochemical effects in mice. Biochem Pharmacol 37:2613","journal-title":"Biochem Pharmacol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0163-7258(89)90115-0","volume":"41","author":"JW Darnowski","year":"1989","unstructured":"Darnowski JW, Handschumacher RE (1989) Enhancement of fluorouracil therapy by the manipulation of tissue uridine pools. Pharmacol Ther 41:381","journal-title":"Pharmacol Ther"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/0006-2952(91)90146-V","volume":"41","author":"JW Darnowski","year":"1991","unstructured":"Darnowski JW, Handschumacher RE, Wiegand RA, Goulette FA, Calabresi P (1991) Tissue-specific expansion of uridine pools in mice. Effects of benzylacyclouridine, dipyridamole and exogenous uridine. Biochem Pharmacol 41:2031","journal-title":"Biochem Pharmacol"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0006-2952(93)90390-I","volume":"45","author":"ST Davis","year":"1993","unstructured":"Davis ST, Joyner SS, Chandrasurin P, Baccanari DP (1993) Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine. Biochem Pharmacol 45:173","journal-title":"Biochem Pharmacol"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0041-008X(75)90268-9","volume":"31","author":"C Dwivedi","year":"1975","unstructured":"Dwivedi C, Harbison RD (1975) Anticonvulsant activities of \u0394-8 and \u0394-9 tetrahydrocannabinol and uridine. Toxicol Appl Pharmacol 31:452","journal-title":"Toxicol Appl Pharmacol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/0006-2952(90)90089-4","volume":"40","author":"MH el Kouni","year":"1990","unstructured":"el Kouni MH, Naguib FNM, Park KS, Cha S, Darnowski JW, Soong S-J (1990) Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice. Biochem Pharmacol 40:2479","journal-title":"Biochem Pharmacol"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0006-2952(00)00410-X","volume":"60","author":"MH el Kouni","year":"2000","unstructured":"el Kouni MH, Goudgaon NM, Rafeeq M, Al Safarjalani ON, Schinazi RF, Naguib FNM (2000) 5-Phenylthioacyclouridine: a potent and specific inhibitor of uridine phosphorylase. Biochem Pharmacol 60:851","journal-title":"Biochem Pharmacol"},{"key":"CR27","first-page":"46","volume":"11","author":"H Elrick","year":"1962","unstructured":"Elrick H, Hlad CJ Jr, Arai Y (1962) Influence of certain nucleosides on glucose metabolism in man. Metabolism 11:46","journal-title":"Metabolism"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1182\/blood.V76.11.2216.2216","volume":"76","author":"A Falcone","year":"1990","unstructured":"Falcone A, Darnowski JW, Ruprecht RM, Chu SH, Burnetti I, Calabresi P (1990) Differential effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice. Blood 76:2216","journal-title":"Blood"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0404.1992.tb08045.x","volume":"86","author":"V Gallai","year":"1992","unstructured":"Gallai V, Mazzotta G, Montesi S, Sarchielli P, Del Gatto F (1992) Effects of uridine in the treatment of diabetic neuropathy: an electrophysiological study. Acta Neurol Scand 86:3","journal-title":"Acta Neurol Scand"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.7256279","volume":"213","author":"T Gasser","year":"1981","unstructured":"Gasser T, Moyer JD, Handschumacher RE (1981) Novel single-pass exchange of circulating uridine in rat liver. Science 213:777","journal-title":"Science"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1471-4159.1956.tb12059.x","volume":"1","author":"A Geiger","year":"1956","unstructured":"Geiger A, Yamasaki S (1956) Cytidine and uridine requirement of the brain. J Neurochem 1:93","journal-title":"J Neurochem"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0006-2952(95)00255-X","volume":"50","author":"S Greene","year":"1995","unstructured":"Greene S, Watanabe K, Braatz-Trulson J, Lou L (1995) Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent, leflunomide. Biochem Pharmacol 50:861","journal-title":"Biochem Pharmacol"},{"key":"CR33","first-page":"180","volume-title":"Cancer chemotherapy; principles and practice","author":"JL Grem","year":"1990","unstructured":"Grem JL (1990) Fluorinated pyrimidines. In: Chabner BA, Collins JM (eds) Cancer chemotherapy; principles and practice. JB Lippincott Co., Philadelphia, p 180"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/BF00964155","volume":"8","author":"P Guarneri","year":"1983","unstructured":"Guarneri P, Guarner R, Mocciaro C, Piccoli F (1983) Interaction of uridine with GABA binding sites in cerebellar membranes of the rat. Neurochem Res 8:1537","journal-title":"Neurochem Res"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1528-1157.1985.tb05709.x","volume":"26","author":"P Guarneri","year":"1985","unstructured":"Guarneri P, Guarner R, Mocciaro C, Piccoli F (1985) Interaction of uridine with GABA-mediated inhibitory transmission: studies in vivo and in vitro. Epilepsia 26:666","journal-title":"Epilepsia"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1200\/JCO.2000.18.1.167","volume":"18","author":"M Hidalgo","year":"2000","unstructured":"Hidalgo M, Villalona-Calero MA, Eckhardt SG, Drengler RL, Rodriguez G, Hammond LA, Diab SG, Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O\u2019Neil JD, von Borstel R, Von Hoff DD, Rowinsky EK (2000) Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J Clin Oncol 18:167","journal-title":"J Clin Oncol"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1432-1033.1985.tb08907.x","volume":"149","author":"A Holstege","year":"1985","unstructured":"Holstege A, Leser H-G, Pausch J, Gerok W (1985) Uridine catabolism in Kupffer cells, endothelial cells, and hepatocytes. Eur J Biochem 149:169","journal-title":"Eur J Biochem"},{"key":"CR38","first-page":"5576","volume":"46","author":"A Holstege","year":"1986","unstructured":"Holstege A, Pausch J, Gerok W (1986) Effect of 5-diazouracil on the catabolism of circulating pyrimidines in rat liver and kidneys. Cancer Res 46:5576","journal-title":"Cancer Res"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0168-8278(92)90180-W","volume":"14","author":"A Holstege","year":"1992","unstructured":"Holstege A, Gengenbacher H-M, Jehle L, Gerok W (1992) Uridine catabolism by the isolated perfused rat liver. J Hepatol 14:335","journal-title":"J Hepatol"},{"key":"CR40","first-page":"557","volume":"10","author":"S Inou\u00e9","year":"1993","unstructured":"Inou\u00e9 S (1993) Sleep-promoting substance (SPS) and physiological sleep regulation. Zool Sci 10:557","journal-title":"Zool Sci"},{"key":"CR41","first-page":"2092","volume":"60","author":"G Jann","year":"1969","unstructured":"Jann G, Delzanno GB (1969) Azione della citidina ed uridina nel trattamento delle indromi neuropsichiche da encefalopatie di varia origine. Minerva Med 60:2092","journal-title":"Minerva Med"},{"key":"CR42","first-page":"702","volume":"44","author":"SA Keilbauch","year":"1993","unstructured":"Keilbauch SA, Hobbs GA, Simpson MV (1993) Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2\u2032,3\u2032-dideoxycytidine toxicity in PC12 cells, a neuronal model by uridine and pyruvate. Mol Pharmacol 44:702","journal-title":"Mol Pharmacol"},{"key":"CR43","first-page":"1045","volume-title":"The metabolic basis of inherited disease","author":"WN Kelly","year":"1978","unstructured":"Kelly WN, Smith LH Jr (1978) Hereditary orotic aciduria. In: Stanbury JB, Wyngaarden JB, Fredrickson DS (eds) The metabolic basis of inherited disease, 4th edn. McGraw-Hill Book Co, New York, NY, p 1045","edition":"4"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1200\/JCO.1997.15.4.1511","volume":"15","author":"DP Kelsen","year":"1997","unstructured":"Kelsen DP, Martin D, O\u2019Neil J, Schwartz G, Saltz L, Sung MT, von Borstel R, Bertino J (1997) Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with avoidance responding. J Clin Oncol 15:1511","journal-title":"J Clin Oncol"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF00292865","volume":"8","author":"P Klubes","year":"1982","unstructured":"Klubes P, Cerna I, Meldon MA (1982) Uridine rescue from the lethal toxicity of 5-fluorouracil in mice. Cancer Chemother Pharmacol 8:17","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR46","first-page":"3182","volume":"43","author":"P Klubes","year":"1983","unstructured":"Klubes P, Cerna I (1983) Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil. Cancer Res 43:3182","journal-title":"Cancer Res"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/BF00256691","volume":"17","author":"P Klubes","year":"1986","unstructured":"Klubes P, Geffen DB, Cysyk RL (1986) Comparison of the bioavailability of uridine in mice after either oral or parenteral administration. Cancer Chemother Pharmacol 17:236","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/135965350300800516","volume":"8","author":"EC Koch","year":"2003","unstructured":"Koch EC, Schneider J, Weis R, Penning B, Walker UA (2003) Uridine excess does not interfere with the antiretroviral efficacy of nucleoside analogue reverse transcriptase inhibitors. Antivir Ther 8:485","journal-title":"Antivir Ther"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/archpsyc.61.3.300","volume":"61","author":"C Konradi","year":"2004","unstructured":"Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S (2004) Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 61:300","journal-title":"Arch Gen Psychiatry"},{"key":"CR50","first-page":"565","volume":"199","author":"J Kypson","year":"1976","unstructured":"Kypson J, Hait G (1976) Effects of uridine and inosine on glucose metabolism in skeletal muscle and activated lipolysis in adipose tissue. J Pharmacol Exp Ther 199:565","journal-title":"J Pharmacol Exp Ther"},{"key":"CR51","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/0006-2952(77)90073-9","volume":"26","author":"J Kypson","year":"1977","unstructured":"Kypson J, Hait G (1977) Metabolic effects of inosine and uridine in rabbit hearts and rat skeletal muscles. Biochem Pharmacol 26:1585","journal-title":"Biochem Pharmacol"},{"key":"CR52","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/0022-2828(78)90013-5","volume":"10","author":"J Kypson","year":"1978","unstructured":"Kypson J, Hait G, Mathew R (1978) Effects of uridine on the performance and the metabolism of oxygenated and hypoxic rabbit hearts. J Mol Cell Cardiol 10:545","journal-title":"J Mol Cell Cardiol"},{"key":"CR53","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1328-0163(97)90029-4","volume":"6","author":"Z Lin","year":"1997","unstructured":"Lin Z, Richards S, Rosenfeldt F, Pepe S (1997) Uridine preserves ATP during hypoxic perfusion of the rat heart. Asia Pacific Heart 6:190","journal-title":"Asia Pacific Heart"},{"key":"CR54","first-page":"5928","volume":"44","author":"A Leyva","year":"1984","unstructured":"Leyva A, van Groeningen CJ, Kraal I, Peters GJ, Lankelma J, Pinedo HM (1984) Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity. Cancer Res 44:5928","journal-title":"Cancer Res"},{"key":"CR55","first-page":"3964","volume":"42","author":"DS Martin","year":"1982","unstructured":"Martin DS, Stolfi RL, Sawyer RC, Spiegelman S, Young CW (1982) High-dose 5-fluorouracil with delayed uridine \u201crescue\u201d in mice. Cancer Res 42:3964","journal-title":"Cancer Res"},{"key":"CR56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00254098","volume":"24","author":"DS Martin","year":"1989","unstructured":".Martin DS, Stolfi RL, Sawyer RC (1989) Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother Pharmacol 24:9","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR57","first-page":"91","volume":"25","author":"FZ Meerson","year":"1985","unstructured":"Meerson FZ, Dosmagabetova RS (1985) The use of glucose and uridine to control contractility and extensibility disturbances in the nonischemized compartments of the heart in myocardial infarction. Kardiologiya 25:91","journal-title":"Kardiologiya"},{"key":"CR58","first-page":"R465","volume":"242","author":"A Monks","year":"1982","unstructured":"Monks A, Cysyk RL (1982) Uridine regulation by the isolated rat liver: perfusion with an artificial oxygen carrier. Am J Physiol 242:R465","journal-title":"Am J Physiol"},{"key":"CR59","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/0006-2952(83)90419-7","volume":"32","author":"A Monks","year":"1983","unstructured":"Monks A, Ayers O, Cysyk RL (1983) Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver. Biochem Pharmacol 32:2003","journal-title":"Biochem Pharmacol"},{"key":"CR60","first-page":"4348","volume":"57","author":"GF Monticone","year":"1966","unstructured":"Monticone GF, Bergamasco B, Congnazzo A (1966) Sull\u2019impiego terapeutico dei nucleosidi citidina ed uridina in alcune affezioni neurologiche. Minerva Med 57:4348","journal-title":"Minerva Med"},{"key":"CR61","first-page":"3010","volume":"41","author":"JD Moyer","year":"1981","unstructured":"Moyer JD, Oliver JT, Handschumacher RE (1981) Salvage of circulating pyrimidine nucleosides in the rat. Cancer Res 41:3010","journal-title":"Cancer Res"},{"key":"CR62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3181\/00379727-204-43633","volume":"204","author":"CS Myers","year":"1993","unstructured":"Myers CS, Napolitano M, Fisher H, Wagner GC (1993) Uridine and stimulant-induced motor activity. Proc Soc Exp Biol Med 204:49","journal-title":"Proc Soc Exp Biol Med"},{"key":"CR63","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0006-8993(94)90697-1","volume":"651","author":"CS Myers","year":"1994","unstructured":"Myers CS, Fisher H, Wagner GC (1994) Uridine potentiates haloperidol\u2019s disruption of conditioned avoidance responding. Brain Res 651:194","journal-title":"Brain Res"},{"key":"CR64","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0006-2952(93)90141-I","volume":"45","author":"FNM Naguib","year":"1993","unstructured":"Naguib FNM, Soong S-j, el Kouni MH (1993) Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver: possible relevance to chemotherapy with 5-fluoropyrimidines. Biochem Pharmacol 45:667","journal-title":"Biochem Pharmacol"},{"key":"CR65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0165-2478(95)02464-6","volume":"48","author":"RV Nair","year":"1995","unstructured":"Nair RV, Cao W, Morris RE (1995) Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Immunol Lett 48:77","journal-title":"Immunol Lett"},{"key":"CR66","doi-asserted-by":"crossref","first-page":"11601","DOI":"10.1073\/pnas.94.21.11601","volume":"94","author":"T Page","year":"1997","unstructured":"Page T, Yu A, Fontanesi J, Nyhan WL (1997) Developmental disorder associated with increased cellular nucleotidase activity. Proc Natl Acad Sci U S A 94:11601","journal-title":"Proc Natl Acad Sci U S A"},{"key":"CR67","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/oxfordjournals.annonc.a057994","volume":"2","author":"GJ Peters","year":"1991","unstructured":"Peters GJ, van Groeningen CJ (1991) Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 2:469","journal-title":"Ann Oncol"},{"key":"CR68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1016410817898","volume":"4","author":"GJ Peters","year":"1987","unstructured":"Peters GJ, van Groeningen CJ, Laurensse EJ, Lankelma J, Kraal I, Leyva A, Lankelma J, Pinedo HM (1987) Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data. Pharm Res 4:113","journal-title":"Pharm Res"},{"key":"CR69","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00253962","volume":"20","author":"GJ Peters","year":"1987","unstructured":"Peters GJ, van Groeningen CJ, Laurensse E, Levya A, Pinedo HM (1987) Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemother Pharmacol 20:101","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR70","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/bjc.1988.56","volume":"57","author":"GJ Peters","year":"1988","unstructured":"Peters GJ, van Dijk J, Laurensse E, van Groeningen CJ, Lankelman J, Levya A, Nadal JC, Pinedo HM (1988) In vitro biochemical and in vivo biological studies of the uridine \u201crescue\u201d of 5-fluorouracil. Br J Cancer 57:259","journal-title":"Br J Cancer"},{"key":"CR71","first-page":"1165","volume":"4","author":"G Pizzorno","year":"1998","unstructured":"Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MYW, Chu HS, Chu E, Leffert JJ, Handschumacher RE, Calabresi P (1998) Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res 4:1165","journal-title":"Clin Cancer Res"},{"key":"CR72","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0006-8993(73)90296-5","volume":"55","author":"CA Roberts","year":"1973","unstructured":"Roberts CA (1973) Anticonvulsant effects of uridine: comparative analysis of metrazol and penicillin induced foci. Brain Res 55:291","journal-title":"Brain Res"},{"key":"CR73","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1528-1157.1974.tb04023.x","volume":"15","author":"CA Roberts","year":"1974","unstructured":"Roberts CA, Kreisman NR, Waltman M (1974) Uridine anticonvulsant effects: selective control of nucleoside incorporation in experimental epilepsy. Epilepsia 15:479","journal-title":"Epilepsia"},{"key":"CR74","first-page":"3352","volume":"56","author":"I Sanguineti","year":"1965","unstructured":"Sanguineti I, Zerbi D (1965) L\u2019impiego di alcuni nucleosidi non vasoattivi (citidina e uridina) nella terapia delle vasculopatie cerebrali. Minerva Med 56:3352","journal-title":"Minerva Med"},{"key":"CR75","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainres.2003.09.049","volume":"994","author":"JA Saydoff","year":"2003","unstructured":"Saydoff JA, Liu LS, Garcia RA, Hu Z, Li D, von Borstel RW (2003) Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington\u2019s disease. Brain Res 994:44","journal-title":"Brain Res"},{"key":"CR76","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/1097-0142(19930301)71:5<1875::AID-CNCR2820710526>3.0.CO;2-9","volume":"71","author":"K Seiter","year":"1993","unstructured":"Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J, Sawyer R (1993) Uridine allows dose escalation of 5-fluorouracil when given with N-phosphoacetyl-L-aspartate, methotrexate, and leucovorin. Cancer 71:1875","journal-title":"Cancer"},{"key":"CR77","first-page":"5934","volume":"61","author":"O Sepe","year":"1970","unstructured":"Sepe O (1970) Efficacia dell\u2019assoiazione citidina-uridina nelle affezioni vascolari dell\u2019encefalo. Minerva Med 61:5934","journal-title":"Minerva Med"},{"key":"CR78","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1128\/AAC.32.7.997","volume":"32","author":"J-P Sommadossi","year":"1988","unstructured":"Sommadossi J-P, Carlisle R, Schinazi RF, Zhou Z (1988) Uridine reverses the toxicity of 3\u2032-azido-3\u2032-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother 32:997","journal-title":"Antimicrob Agents Chemother"},{"key":"CR79","first-page":"63","volume-title":"Advances in Chemotherapy of AIDS.","author":"J-P Sommadossi","year":"1990","unstructured":"Sommadossi J-P, Zhu Z, Carlisle R, Xie MY, Weidner DA, el Kouni MH (1990) Novel pharmacologic approaches for the treatment of AIDS and potential use of uridine phosphorylase inhibitors. In: Diasio RB, Sommadossi J-P (eds) Advances in chemotherapy of AIDS. Pergamon Press, NY, p 63"},{"key":"CR80","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF00685624","volume":"37","author":"J-P Sommadossi","year":"1995","unstructured":"Sommadossi J-P, Cretton EM, Kidd LB, McClure HM, Anderson DC, el Kouni MH (1995) Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy. Cancer Chemother Pharmacol 37:14","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0026-0495(81)90159-1","volume":"30","author":"E Songu","year":"1980","unstructured":"Songu E, Haugaard ES, Wildley G, Haugaard N (1980) The relationship between uracil nucleotide concentrations and glycogen synthesis in hepatocytes from fed and fasted rats. Metabolism 30:119","journal-title":"Metabolism"},{"key":"CR82","first-page":"587","volume":"79","author":"K Tamura","year":"1993","unstructured":"Tamura K, Woo J, Bakri MT, Thomson AW (1993) Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells. Immunology 79:587","journal-title":"Immunology"},{"key":"CR83","first-page":"745","volume":"70","author":"CJ Groeningen van","year":"1986","unstructured":"van Groeningen CJ, Leyva A, Kraal I, Peters GJ, Pinedo HM (1986) Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. Cancer Treat Rep 70:745","journal-title":"Cancer Treat Rep"},{"key":"CR84","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/jnci\/81.2.157","volume":"81","author":"CJ Groeningen van","year":"1989","unstructured":"van Groeningen CJ, Peters GJ, Leyva A, Laurensse E, Pinedo HM (1989) Reversal of 5-fluorouracil induced myelosuppression by prolonged administration of high-dose uridine. J Natl Cancer Inst 81:157","journal-title":"J Natl Cancer Inst"},{"key":"CR85","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnci\/83.6.437","volume":"83","author":"CJ Groeningen van","year":"1991","unstructured":"van Groeningen CJ, Peters GJ, Nadal JC, Leyva A, Laurensse E, Pinedo HM (1991) Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst 83:437","journal-title":"J Natl Cancer Inst"},{"key":"CR86","first-page":"148","volume":"19","author":"CJ Groeningen van","year":"1992","unstructured":"van Groeningen CJ, Peters GJ, Pinedo HM (1992) Modulation of fluorouracil toxicity with uridine. Semin Oncol 19:148","journal-title":"Semin Oncol"},{"key":"CR87","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/135965350300800514","volume":"8","author":"UA Walker","year":"2003","unstructured":"Walker UA, Venhoff N, Koch EC, Olschewski M, Schneider J, Setzer B (2003) Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 8:463","journal-title":"Antivir Ther"},{"key":"CR88","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/00002030-200404300-00025","volume":"18","author":"UA Walker","year":"2004","unstructured":"Walker UA, Langman P, Miehle N, Zilly M, Klinker H, Petschner F (2004) Beneficial effects of oral uridine in mitochondrial toxicity. AIDS 18:1085","journal-title":"AIDS"},{"key":"CR89","doi-asserted-by":"crossref","first-page":"22467","DOI":"10.1074\/jbc.270.38.22467","volume":"270","author":"RA Williamson","year":"1995","unstructured":"Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, Woodward K, Bruneau J-M, Hambleton P, Moss D, Thomson TA, Spinella-Jaegle S, Morand P, Courtin O, Saut\u00e9s C, Westwood R, Hercend T, Kuo EA, Ruuth E (1995) Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 270:22467","journal-title":"J Biol Chem"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0967-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-004-0967-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-004-0967-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T08:18:40Z","timestamp":1683015520000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-004-0967-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,24]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s00280-004-0967-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,24]]}}}